Tectonic Therapeutic, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 13, 2019 and accepted by EDGAR at May 13, 2019, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-01-01 to 2019-03-31 | $12.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | −$17.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$17.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | −$0.72 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$17.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $340.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-03-31 | $108.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $113.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $117.4m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $9.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $10.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-03-31 | $106.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-19-145337. Last ingested by Listed: Nov 5, 2026, 19:21 ET. Listed shows no prices and gives no investment advice.